Welcome to the October edition of the Mantle Cell Lymphoma Alliance newsletter!
Behind the scenes at MCLA, we have been working on our scientific priorities, building connections with other blood cancer non-profits, and laying the groundwork for our participation at this year's American Society of Hematology (ASH) Conference in December 2026. We are also pleased to announce our second Founding Partner: BeOne Medicines. We are thankful for BeOne's financial support.
In more unfortunate news, MCLA is disappointed by the UK's National Institute for Health and Care Excellence (NICE) decision to reject Tecartus as a treatment for relapsed MCL. We will explore opportunities to collaborate with the blood cancer community to demonstrate the meaningful impact of CAR T-cell therapy for patients living with mantle cell lymphoma.
In this issue, you'll find our regular "Ask the Expert" feature, a patient profile, our statement about NICE's denial of Tecartus for relapsed MCL, a trial update in our Research Corner, and a look ahead at events in November.
As always, thank you for being part of the MCLA community.
Ask the Expert
I see some patients with mantle cell lymphoma taking venetoclax or other BCL-2 inhibitors alongside BTK inhibitors. What are these drugs, and should I expect them if my MCL relapses after initial chemotherapy?
Answer reviewed by Dr. Michael E. Williams, MD, ScM, FACP, University of Virginia.
BCL-2 inhibitors are newer cancer drugs that help trigger cancer cell death. Researchers are studying whether combining them with BTK inhibitors, such as acalabrutinib and zanubrutinib, can produce longer remissions in patients with MCL.
The phase 3 SYMPATICO trial compared the BTK inhibitor ibrutinib alone with ibrutinib plus the BCL-2 inhibitor venetoclax in 267 patients whose MCL had returned or stopped responding to treatment.
The results were encouraging. Patients receiving the combination went a median of 31.9 months before their cancer progressed, versus 22.1 months for ibrutinib alone. Complete remission rates were also higher (54% versus 32%), with benefits even among higher-risk patients, including those with TP53 mutations.
However, the combination increased certain side effects. Severe neutropenia (low infection-fighting white blood cells) occurred in 31% of combination patients versus 11% receiving ibrutinib alone.
So are BCL-2 inhibitors available at first relapse?
Not as an FDA-approved treatment. Despite SYMPATICO's promising results, venetoclax is not FDA-approved for MCL. Another BCL-2 inhibitor, sonrotoclax, received accelerated FDA approval in May, but only for patients who have received at least two prior treatments, including a BTK inhibitor.
Patients at first relapse would therefore generally receive an established treatment, such as a BTK inhibitor alone, rather than a BTKi/BCL-2i combination. Those interested in combination therapy may be able to access it through a clinical trial.
One study to watch is the phase 3 CELESTIAL trial, comparing zanubrutinib alone with zanubrutinib plus sonrotoclax in relapsed MCL. Positive results could support FDA approval for sonrotoclax after first relapse.
Also of interest is the phase 3 MANGROVE trial comparing zanubrutinib plus rituximab to bendamustine plus rituximab in patients with previously untreated MCL; the results will be reported at the upcoming American Society of Hematology meeting in December 2026. Other "chemo-free" regimens incorporating BTKi and BCL-2i are being tested in clinical trials.
Bottom line: BCL-2 inhibitors are promising treatments that can extend remissions when combined with BTK inhibitors. Although these combinations are not yet approved for second-line MCL, they may be available through trials and will hopefully become available in the second line in the future.
Patient Profile: Chris H.
In September 2020, I was 46, with 13-year-old twin girls, when a surgeon told me the "hernia" I was about to have fixed was mantle cell lymphoma. I looked up survival rates that night and wanted to throw up.
Here's what happened after that:
Read Chris' story →MCLA's Statement on the Denial of Tecartus as Approved Treatment for MCL in the UK
On October 23, the UK's National Institute for Health and Care Excellence (NICE) upheld its decision not to recommend Tecartus, a CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma (MCL) despite appeals from its manufacturer and three leading blood cancer charities. Although NICE acknowledged the treatment's clinical effectiveness, it concluded that uncertainty about the extent of its benefits prevented it from being considered a cost-effective use of NHS resources.
This is deeply disappointing news for the MCL community. We stand with Lymphoma Action, Anthony Nolan, Blood Cancer UK, and all those who advocated for continued access to Tecartus.
For patients with relapsed or refractory MCL, treatment options are limited, and CAR-T therapy can offer the possibility of long-term remission. One of MCLA's cofounders was involved in advocating alongside these organizations, making this decision particularly meaningful to us.
Rare cancers present unique challenges in generating the evidence required for treatment approval and reimbursement. Patients should not be disadvantaged simply because their disease is rare.
We remain committed to working alongside our fellow advocacy organizations to ensure that the voices of MCL patients are heard and that access to promising treatments remains a priority.
Research Corner: BTK Inhibitors in Frontline Treatment
Compiled by MCLA. Reviewed by Annie Xiao, MD, City of Hope, Duarte, CA
Last month, we featured a trial showing continued benefit from adding the BTK inhibitor acalabrutinib (Calquence) to bendamustine and rituximab (BR) as an initial treatment for older adults with MCL. This month, we feature another trial showing the success of adding BTK inhibitors to frontline chemotherapy.
Specifically, a new trial found high response rates with a first-line treatment called CARiBOU for patients with MCL. The regimen combines several established MCL treatments, including the chemotherapy drug cytarabine, with a targeted drug, BTK inhibitor acalabrutinib.
Among 41 patients, 90% achieved a complete metabolic response, meaning no active lymphoma could be detected on PET imaging after treatment.
Learn more →MCLA Connections
Living with mantle cell lymphoma can feel isolating, whether you are the patient or the person standing beside them. MCLA Connections is a chance to spend time with others who understand, hear from the community, and leave knowing you are not doing this alone.
Please join us via Zoom for a gathering of MCL patients and caregivers. Our first conversation is simply Living with MCL. We'll talk about what life with MCL—or caring for someone with it—has been like, what support has helped, and what we hope to find by connecting with one another. Details below:
Thursday, November 5 at 7:00 PM Eastern
Friday, November 6 at 12:00 PM Eastern
Register here →Oncologist Webinar: MCL: The Journey's Facebook Support Group Lecture Series
Date: November 16 at 1:00–2:00 PM EST
Description: Drs. Yucai Wang of Mayo Clinic and Anita Kumar of Memorial Sloan Kettering (participation pending) will speak about MCL updates from recent hematology conferences and the treatment of TP53-positive MCL.
Register on MCLA's website: Sign-up Form Coming Soon
We are grateful for our Founding Partners' financial support:
